ganaxolone-neuropsychiatric-disorders.jpg

Dedicated to the
Development of
Ganaxolone

A new mechanism of action designed with selectivity and safety in mind.

Extensive Safety Database

Ganaxolone has been studied in more than 1,600 subjects, both pediatric and adult, at therapeutically relevant dose levels and treatment regimens for up to two years. In these studies, ganaxolone was generally safe and well tolerated, with the most commonly reported adverse events of somnolence, dizziness, and fatigue.

Find a Clinical Trial

icon ganaxolone study

Ganaxolone has been studied in more than 1,600 subjects, both pediatric and adult